Drug Trial Radar · NCT03402165
Serum Alpha-fetoprotein Levels and Response to Direct Antiviral Therapy in Patients With Chronic Hepatitis C
Last checked: Nov 19, 2026Latest source record: Aug 27, 2018 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
1,200
Planned (sponsor's estimate)
Start
Jan 1, 2017
Primary completion
Dec 1, 2022
Study completion Dec 30, 2022
Sponsor
- Lead sponsor
- Sherief Abd-ElsalamAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Jan 18, 2018
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Alpha-fetoprotein Levels on the Response to direct Antiviral Therapy in Patients with Chronic Hepatitis C
Conditions
- Hepatitis C
Interventions
Sofosbuvir and Ledipasvir or sofosbuvir and daklatasuvirDrug
Response to DAAD's and developing HCC
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of patients with sustained virologic responseTime frame: 6 months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Sherief Abd-Elsalam
Tanta, Egypt · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.